Tibi Ahmad Al, Hasan Diya, Al-Sanabra Ola M, Mansour Ghaith H, Shawagfeh Maissa T, Alqaraleh Moath, AlRamadneh Tareq Nayef, Al-Khreisat Mutaz Jamal, Burghel George J, Abdelnour Amid
Biolab Diagnostic Laboratories, Amman, Jordan.
Department of Allied Medical Sciences, Zarqa College, Al-Balqa Applied University, Zarqa, Jordan.
J Clin Med Res. 2025 Apr;17(4):231-239. doi: 10.14740/jocmr6213. Epub 2025 Apr 19.
β-Thalassemia is a genetic disorder characterized by decreased or completely absent β-globin synthesis, leading to a spectrum of clinical manifestations. It is a major public health concern in Jordan, as in other Mediterranean countries. β-Thalassemia carriers are normally asymptomatic; nevertheless, laboratory examinations often reveal mild anemia characterized by microcytic hypochromic erythrocytes, with differences influenced by specific phenotypes. This study aimed to assess and correlate the variants among β and β phenotypes in the Jordanian population with hematological characteristics, as well as establish and determine reference values for distinguishing between the two phenotypes.
One hundred forty-five β-thalassemia carriers were recruited from various governorates in Jordan. Hematological parameters, including complete blood count (CBC) and capillary electrophoresis of hemoglobin (Hb), were evaluated in all participants. Molecular techniques, specifically polymerase chain reaction (PCR) with hybridization, were employed to identify β-thalassemia variants and classify the participants as having β and β phenotypes.
Among the 145 β-thalassemia carriers, 64 (44.14%) and 81 (55.86%) had β-thalassemia and β-thalassemia, respectively. Participants exhibiting a cutoff value of Hb (≤ 11.0 g/dL), mean corpuscular volume (MCV) (≤ 64.0 fL), mean corpuscular hemoglobin (MCH) (≤ 19.0 pg), and hemoglobin A (Hb-A) (≥ 5.00%) were classified as having the β phenotype. These participants demonstrated significantly lower mean Hb, MCV, MCH, and higher mean Hb-A than the participants with the β phenotype (P < 0.0001).
Hb, MCV, MCH, and Hb-A can serve as effective screening tools for predicting β- and β-thalassemia in the Jordanian population. These findings have important clinical implications for early diagnosis, genetic counseling, and prenatal screening of β-thalassemia.
β地中海贫血是一种遗传性疾病,其特征为β珠蛋白合成减少或完全缺失,导致一系列临床表现。与其他地中海国家一样,它是约旦的一个主要公共卫生问题。β地中海贫血携带者通常无症状;然而,实验室检查常显示以小细胞低色素红细胞为特征的轻度贫血,其差异受特定表型影响。本研究旨在评估约旦人群中β和β表型之间的变异与血液学特征的相关性,并建立和确定区分这两种表型的参考值。
从约旦各省份招募了145名β地中海贫血携带者。对所有参与者评估了血液学参数,包括全血细胞计数(CBC)和血红蛋白(Hb)的毛细管电泳。采用分子技术,特别是聚合酶链反应(PCR)结合杂交,来鉴定β地中海贫血变异,并将参与者分类为具有β和β表型。
在145名β地中海贫血携带者中,分别有64名(44.14%)和81名(55.86%)患有β地中海贫血和β地中海贫血。血红蛋白(Hb)临界值(≤11.0 g/dL)、平均红细胞体积(MCV)(≤64.0 fL)、平均红细胞血红蛋白(MCH)(≤19.0 pg)和血红蛋白A(Hb-A)(≥5.00%)的参与者被分类为具有β表型。这些参与者的平均Hb、MCV、MCH显著低于具有β表型的参与者,而平均Hb-A则更高(P<0.0001)。
Hb、MCV、MCH和Hb-A可作为预测约旦人群中β和β地中海贫血的有效筛查工具。这些发现对β地中海贫血的早期诊断、遗传咨询和产前筛查具有重要的临床意义。